Business Description
ARCA biopharma Inc
NAICS : 325413
SIC : 2835
ISIN : US00211Y4070
Description
ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 183.49 | |||||
| Equity-to-Asset | 0.98 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.03 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 37.6 | |||||
| 3-Year EPS without NRI Growth Rate | 43.7 | |||||
| 3-Year FCF Growth Rate | 40.4 | |||||
| 3-Year Book Growth Rate | -19.4 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 68.1 | |||||
| 9-Day RSI | 73.08 | |||||
| 14-Day RSI | 75.17 | |||||
| 6-1 Month Momentum % | -12.76 | |||||
| 12-1 Month Momentum % | -14.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 59.01 | |||||
| Quick Ratio | 59.01 | |||||
| Cash Ratio | 58.76 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -14.9 | |||||
| Shareholder Yield % | 0.16 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -13.59 | |||||
| ROA % | -13.13 | |||||
| ROIC % | -1508.68 | |||||
| ROC (Joel Greenblatt) % | -2347.49 | |||||
| ROCE % | -18.46 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.4 | |||||
| Price-to-Tangible-Book | 1.4 | |||||
| EV-to-EBIT | -2.01 | |||||
| EV-to-EBITDA | -2.04 | |||||
| EV-to-FCF | -2.93 | |||||
| Price-to-Net-Current-Asset-Value | 1.42 | |||||
| Price-to-Net-Cash | 1.42 | |||||
| Earnings Yield (Greenblatt) % | -49.75 | |||||
| FCF Yield % | -9.66 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ABIO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ARCA biopharma Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.37 | ||
| Beta | -0.03 | ||
| Volatility % | 18.28 | ||
| 14-Day RSI | 75.17 | ||
| 14-Day ATR ($) | 0.205274 | ||
| 20-Day SMA ($) | 3.1365 | ||
| 12-1 Month Momentum % | -14.5 | ||
| 52-Week Range ($) | 1.56 - 3.88 | ||
| Shares Outstanding (Mil) | 14.5 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ARCA biopharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ARCA biopharma Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
ARCA biopharma Inc Frequently Asked Questions
What is ARCA biopharma Inc(ABIO)'s stock price today?
The current price of ABIO is $3.58. The 52 week high of ABIO is $3.88 and 52 week low is $1.56.
When is next earnings date of ARCA biopharma Inc(ABIO)?
The next earnings date of ARCA biopharma Inc(ABIO) is 2024-07-19 Est..
Does ARCA biopharma Inc(ABIO) pay dividends? If so, how much?
ARCA biopharma Inc(ABIO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers